JP2022502416A5 - - Google Patents

Info

Publication number
JP2022502416A5
JP2022502416A5 JP2021517009A JP2021517009A JP2022502416A5 JP 2022502416 A5 JP2022502416 A5 JP 2022502416A5 JP 2021517009 A JP2021517009 A JP 2021517009A JP 2021517009 A JP2021517009 A JP 2021517009A JP 2022502416 A5 JP2022502416 A5 JP 2022502416A5
Authority
JP
Japan
Prior art keywords
mhc
score
neoepitopes
minimum
epitope
Prior art date
Application number
JP2021517009A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022502416A (ja
JPWO2020065023A5 (https=
JP7585195B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2019/076210 external-priority patent/WO2020065023A1/en
Publication of JP2022502416A publication Critical patent/JP2022502416A/ja
Publication of JP2022502416A5 publication Critical patent/JP2022502416A5/ja
Publication of JPWO2020065023A5 publication Critical patent/JPWO2020065023A5/ja
Application granted granted Critical
Publication of JP7585195B2 publication Critical patent/JP7585195B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021517009A 2018-09-27 2019-09-27 ネオエピトープを選択する方法 Active JP7585195B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18197172.2 2018-09-27
EP18197172 2018-09-27
PCT/EP2019/076210 WO2020065023A1 (en) 2018-09-27 2019-09-27 Method for selecting neoepitopes

Publications (4)

Publication Number Publication Date
JP2022502416A JP2022502416A (ja) 2022-01-11
JP2022502416A5 true JP2022502416A5 (https=) 2022-09-27
JPWO2020065023A5 JPWO2020065023A5 (https=) 2022-09-27
JP7585195B2 JP7585195B2 (ja) 2024-11-18

Family

ID=63794302

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021517009A Active JP7585195B2 (ja) 2018-09-27 2019-09-27 ネオエピトープを選択する方法

Country Status (12)

Country Link
US (1) US12462898B2 (https=)
EP (1) EP3856957A1 (https=)
JP (1) JP7585195B2 (https=)
KR (1) KR102902460B1 (https=)
CN (1) CN112771214B (https=)
AU (1) AU2019346023B2 (https=)
BR (1) BR112021005702A8 (https=)
CA (1) CA3111903A1 (https=)
IL (1) IL281771B2 (https=)
MX (1) MX2021003654A (https=)
SG (1) SG11202101965QA (https=)
WO (1) WO2020065023A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020221783A1 (en) * 2019-04-29 2020-11-05 Vaccibody As Methods for pre-selection of neoepitopes
US20230197192A1 (en) * 2020-11-06 2023-06-22 Amazon Technologies, Inc. Selecting neoantigens for personalized cancer vaccine
GB202102606D0 (en) * 2021-02-24 2021-04-07 Univ Oxford Innovation Ltd Treatment of ovarian cancer minimal residual disease
IL305777A (en) 2021-03-26 2023-11-01 Nykode Therapeutics ASA Medical combination for cancer treatment
WO2022238420A2 (en) 2021-05-10 2022-11-17 Nykode Therapeutics ASA Co-expression of constructs and immunostimulatory compounds
WO2022238381A2 (en) 2021-05-10 2022-11-17 Nykode Therapeutics ASA Immunotherapy constructs for treatment of disease
WO2023244997A1 (en) * 2022-06-13 2023-12-21 The University Of North Carolina At Chapel Hill Compositions and methods for inducing anticancer immunity
EP4608436A1 (en) 2022-10-25 2025-09-03 Nykode Therapeutics ASA Constructs and their use
KR102857635B1 (ko) * 2022-11-08 2025-09-10 인바이츠지노믹스 주식회사 면역원성이 높은 유사체를 디자인하는 방법 및 이를 이용한 장치
WO2024100196A1 (en) 2022-11-09 2024-05-16 Nykode Therapeutics ASA Co-expression of constructs and polypeptides
WO2024216073A1 (en) * 2023-04-14 2024-10-17 The Trustees Of Columbia University In The City Of New York Engineered microbes comprising tumor neoantigen vectors for cancer immunotherapy
US20250232833A1 (en) * 2024-01-13 2025-07-17 Noergaard Anders Kaare Cyclin D1 Based Cancer Vaccine

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012029066A2 (pt) 2010-05-14 2020-09-01 The General Hospital Corporation composições e processos de identificação de neoantígenos específicos de tumor.
HRP20211595T1 (hr) 2011-05-24 2022-01-21 BioNTech SE Individualizirana cjepiva protiv raka
WO2014082729A1 (en) 2012-11-28 2014-06-05 Biontech Ag Individualized vaccines for cancer
CN118750591A (zh) 2013-04-07 2024-10-11 博德研究所 用于个性化瘤形成疫苗的组合物和方法
WO2014180490A1 (en) 2013-05-10 2014-11-13 Biontech Ag Predicting immunogenicity of t cell epitopes
JP6558699B2 (ja) 2013-10-01 2019-08-14 国立大学法人三重大学 抗原提示を促進するエピトープ間配列を含むt細胞誘導ワクチン
US11186640B2 (en) 2014-07-31 2021-11-30 The University Of Western Australia Method for the identification of immunotherapy-drug combinations using a network approach
EP3193892A4 (en) 2014-09-14 2018-09-12 Washington University Personalized cancer vaccines and methods therefor
US10317402B2 (en) 2014-12-03 2019-06-11 Verik Bio, Inc. Identification, selection and use of high curative potential T cell epitopes
WO2016128060A1 (en) * 2015-02-12 2016-08-18 Biontech Ag Predicting t cell epitopes useful for vaccination
CA2988388C (en) * 2015-04-23 2022-11-22 Nantomics, Llc Cancer neoepitopes
SG10201912485PA (en) * 2015-05-13 2020-02-27 Agenus Inc Vaccines for treatment and prevention of cancer
EP3323070B1 (en) * 2015-07-14 2024-05-08 Personal Genome Diagnostics Inc. Neoantigen analysis
RU2729116C2 (ru) 2015-12-16 2020-08-04 Гритстоун Онколоджи, Инк. Идентификация, производство и применение неоантигенов
WO2018136664A1 (en) * 2017-01-18 2018-07-26 Ichan School Of Medicine At Mount Sinai Neoantigens and uses thereof for treating cancer
EP3678699A1 (en) 2017-09-07 2020-07-15 University Of Oslo Vaccine molecules

Similar Documents

Publication Publication Date Title
JP2022502416A5 (https=)
Clark et al. Representation and relative abundance of cell-type selective markers in whole-kidney RNA-Seq data
Adegunsoye et al. Genetics and genomics of pulmonary fibrosis: charting the molecular landscape and shaping precision medicine
Weiss et al. Organization of human and mouse skeletal myosin heavy chain gene clusters is highly conserved
Gutierrez-Arcelus et al. Autoimmune diseases—connecting risk alleles with molecular traits of the immune system
Goldfeder et al. Human genome sequencing at the population scale: a primer on high-throughput DNA sequencing and analysis
King et al. High-quality and high-throughput massively parallel sequencing of the human mitochondrial genome using the Illumina MiSeq
Moll et al. The human keratins: biology and pathology
Nakamura et al. Differential effects of fingolimod on B-cell populations in multiple sclerosis
JP2018524008A (ja) ネオアンチゲン分析
Wong et al. Whole exome sequencing identifies a recurrent RQCD1 P131L mutation in cutaneous melanoma
Blenk et al. Explorative data analysis of MCL reveals gene expression networks implicated in survival and prognosis supported by explorative CGH analysis
TWI758298B (zh) 利用單步驟逆轉錄模板置換pcr之t細胞受體及b細胞受體多樣性解析系統
Liu et al. Etiology of oncogenic fusions in 5,190 childhood cancers and its clinical and therapeutic implication
CN111133115A (zh) 用于其肿瘤携带高过客基因突变负荷的患者的免疫治疗方法
Lee et al. Tumor necrosis factor-α gene polymorphisms in Korean patients with recurrent spontaneous abortion
JP2023540904A (ja) タンパク質および核酸をアッセイするための組成物および方法
Cari et al. Potential effect of tumor-specific Treg-targeted antibodies in the treatment of human cancers: A bioinformatics analysis
JPWO2020065023A5 (https=)
CA3117412A1 (en) Characterization of bone marrow using cell-free messenger-rna
Grinev et al. Decoding of exon splicing patterns in the human RUNX1–RUNX1T1 fusion gene
EP3658689A1 (en) A method for non-invasive prenatal detection of fetal chromosome aneuploidy from maternal blood based on bayesian network
CN112840033A (zh) 肌痛性脑脊髓炎/慢性疲劳综合症(me/cfs)的生物标志物
Lee et al. Human MAIT cells undergo clonal selection and expansion during thymic maturation and aging
Martino et al. Refining high-risk multiple myeloma: advancements in genomic, clinical, and prognostic criteria